si-bone.com - SIBN Company Value to Revenue Ratio

Public company logo of SI-BONE (SIBN)

SI-BONE, Inc. (SIBN) maintains stable cash flows through its monopoly on minimally invasive treatment of the sacroiliac joint. The company's current price-to-sales valuation on this chart on GURU.Markets reflects the asset's dynamics, where 4386.90 is recorded as the baseline value. Market capitalization is driven by the sale of innovative implants, while cost optimization is achieved by outsourcing simple blanks to certified external contractors.

SIBN SI-BONE, Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

SIBN (SI-BONE Corp): analytical breakdowns and indicator data

Fundamental valuation:SI-BONE, Inc. SIBN
Mass-produced product of SI-BONE Inc

To assess the operational strength of assets, it is essential to understand the real value of the business without the influence of debt load. Stable demand for implants makes SI-BONE, Inc. (SIBN) resilient to inflationary shocks. The EV-to-revenue multiple reflects market capitalization and debt relative to sales volume, eliminating emotional noise. Comparing this metric with US industry benchmarks reveals whether the asset is overvalued or undervalued. The trend of this metric confirms the fundamental stability of this defensive medical business.

Competitor analysis for SI-BONE, Inc.

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple AxoGen, Inc. AXGN|Orthofix Medical - EV/Sales Multiple|Enterprise Value to Sales Volume BVS|OrthoPediatrics (KIDS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume TMCI (Treace Corp)|Enterprise Value-to-Revenue Ratio blade.com|Company Value to Revenue Carlsmed Inc (CARL)|EV/Sales Multiple RXST|CLPT - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Stereotaxis, Inc. STXS|STIM: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio